Clinical Data Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts pharminent September 2, 2026
Market Access Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing pharminent September 2, 2026
Clinical Data New data could widen use of AstraZeneca, Amgen immune disease drug pharminent August 27, 2026
M&A / Deals Metsera backers establish new biotech armed with China-licensed immunology asset pharminent August 26, 2026
M&A / Deals China’s Haisco forms immunology biotech with up to $1.5B from American VCs pharminent August 25, 2026
Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026
M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026
M&A / Deals Argenx deepens immuno expertise with $2.2B Forte Biosciences buy pharminent July 27, 2026
Clinical Data Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes pharminent June 30, 2026
Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test pharminent June 11, 2026
Clinical Data Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity pharminent June 4, 2026
Clinical Data AbiVax falls as safety worries cloud ‘landmark’ immune drug results pharminent June 2, 2026
M&A / Deals Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss pharminent May 27, 2026
Pipeline Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update pharminent May 20, 2026
Clinical Data AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis pharminent May 20, 2026
Clinical Data UCB reports positive outcomes for bimekizumab in psoriatic arthritis pharminent May 19, 2026
M&A / Deals Degron adds $40M to series A, supporting immunology plans for molecular glue platform pharminent May 14, 2026
M&A / Deals UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases pharminent May 4, 2026
M&A / Deals Coultreon banks $125M to support testing of former Galapagos immune drug pharminent April 28, 2026
Clinical Data Oruka surges as long-acting psoriasis drug shows early promise pharminent April 27, 2026
Commercial Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change pharminent April 23, 2026
M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies pharminent April 22, 2026